Supplemental Data and Materials: Understanding JAK Inhibitor Toxicity: Is the Off-Target Kinome a Missing Piece of the Puzzle?

The Appendix contains the full results of the Chemical Similarity Ensemble Approach (SEA) analysis for all JAK inhibitors included in this study. This includes FDA-approved agents (ruxolitinib, tofacitinib, baricitinib, abrocitinib, upadacitinib, ritlecitinib) and clinical-stage compounds (povorcitinib). For each molecule, SEA-generated lists of statistically significant predicted off-target kinase interactions are provided in separate supplemental tables (Tables S2–S8), including the target protein, interaction p-value, and known functional role of the kinase where available. These data offer a detailed view of the potential off-target kinome landscape and support the discussion of mechanistic hypotheses proposed in the main text regarding JAK inhibitor tolerability and toxicity.